利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

30 条记录 (耗时 0.022 秒)

    Cyclic CRF antagonists
    3.
    发明授权
    Cyclic CRF antagonists 失效
    循环CRF拮抗剂

    公开(公告)号：US5874227A

    公开(公告)日：1999-02-23

    申请号：US556578

    申请日：1995-11-10

    申请人： Jean E. F. Rivier

    发明人： Jean E. F. Rivier

    IPC分类号： G01N33/15 ,  A61K38/00 ,  A61K38/04 ,  A61K45/00 ,  A61P25/00 ,  A61P29/00 ,  A61P35/00 ,  C07K14/575 ,  G01N33/50 ,  G01N33/566 ,  G01N33/68 ,  G01N33/74 ,  G01N33/53 ,  A61K38/12 ,  A61K38/28 ,  C07K5/00

    CPC分类号： G01N33/5008 ,  C07K14/57509 ,  G01N33/502 ,  G01N33/566 ,  G01N33/68 ,  G01N33/6842 ,  G01N33/74 ,  A61K38/00 ,  G01N2333/5751 ,  Y10S514/805 ,  Y10S930/26

    摘要： Novel cyclic CRF antagonist peptides have the amino acid sequence: ##STR1## wherein Y is Ac, H, Ac-Thr or H-Thr; R.sub.30 is Glu or Cys; R.sub.32 is His or preferably a basic and/or aromatic D-amino acid such as D-His or D-Arg; R.sub.33 is Lys, Orn or Cys. The N-terminus may be extended by Leu or Asp-Leu. CML may be substituted for Leu.sup.27, and D-Tyr may be substituted for D-Phe to facilitate labelling. Lys may be substituted for Arg.sup.23, and its side chain connected by a lactam bridge to Glu.sup.20 to form a bicyclic peptide. Disclosed CRF antagonists include:(cyclo 30-33)�D-Phe.sup.12, Nle.sup.21,38, Glu.sup.30, Lys.sup.33 !r/hCRF(12-41),(cyclo 30-33)�Ac-Thr.sup.11, D-Phe.sup.12, Nle.sup.21,38, Glu.sup.30, Lys.sup.33 !r/hCRF(11-41),(cyclo 30-33)�D-Phe.sup.12, Nle.sup.21,38, Cys.sup.30,33 !r/hCRF(12-41),(bicyclo 20-23,30-33)�D-Phe.sup.12, Nle.sup.21,38, Lys.sup.23,33, Glu.sup.30 !-r/hCRF(12-41),(cyclo 30-33)�D-Phe.sup.12, Nle.sup.21,38, Glu.sup.30, D-His.sup.32, Lys.sup.33 !r/hCRF(12-41),(cyclo 30-30)�D-Phe.sup.12, Nle.sup.21,38, CML.sup.27, Glu.sup.30, D-His.sup.32, Lys.sup.33 !r/hCRF(12-41) and(cyclo 30-30)�D-Phe.sup.12, Nle.sup.21,38, Glu.sup.30, D-Arg.sup.32, Lys.sup.33 !r/hCRF(12-41).Labelled antagonists such as (cyclo 30-30)�I.sup.125 D-Tyr.sup.12, Nle.sup.21,38, Glu.sup.30, D-His.sup.32, Lys.sup.33 !r/hCRF(12-41) are useful in drug screening assays.

    摘要翻译： 新型循环CRF拮抗剂肽具有氨基酸序列：其中Y是Ac，H，Ac-Thr或H-Thr; R30是Glu或Cys; R32是His或优选碱性和/或芳族D-氨基酸，例如D-His或D-Arg; R33是Lys，Orn或Cys。 N末端可以被Leu或Asp-Leu延伸。 CML可以代替Leu27，并且D-Tyr可以被D-Phe取代以便于标记。 Lys可以代替Arg23，其侧链通过内酰胺桥连接至Glu20以形成双环肽。 公开的CRF拮抗剂包括：（环30-33）[D-Phe12，Nle21,38，Glu30，Lys33] r / hCRF（12-41），（环30-33）[Ac-Thr11，D-Phe12，Nle21， 38，Glu30，Lys33] r / hCRF（11-41），（环30-33）[D-Phe12，Nle21,38，Cys30,33] r / hCRF（12-41），（双环20-23,30 -33）[D-Phe12，Nle21,38，Lys23,33，Glu30] -r / hCRF（12-41），（环30-33）[D-Phe12，Nle21,38，Glu30，D-His32，Lys33 ] r / hCRF（12-41），（环30-30）[D-Phe12，Nle21,38，CML27，Glu30，D-His32，Lys33] r / hCRF（12-41）和（环30-30） [D-Phe12，Nle21,38，Glu30，D-Arg32，Lys33] r / hCRF（12-41）。 标记的拮抗剂如（环30-30）[I125D-Tyr12，Nle21,38，Glu30，D-His32，Lys33] r / hCRF（12-41）可用于药物筛选测定。

    Cyclic CRF agonists
    4.
    发明授权
    Cyclic CRF agonists 失效
    循环CRF激动剂

    公开(公告)号：US5844074A

    公开(公告)日：1998-12-01

    申请号：US575148

    申请日：1995-12-19

    申请人： Jean E. F. Rivier

    发明人： Jean E. F. Rivier

    IPC分类号： G01N33/15 ,  A61K38/00 ,  A61K38/04 ,  A61K45/00 ,  A61P25/00 ,  A61P29/00 ,  A61P35/00 ,  C07K14/575 ,  G01N33/50 ,  G01N33/566 ,  G01N33/68 ,  G01N33/74 ,  A61K38/28 ,  A61K38/12 ,  C07K7/64 ,  C07K14/695

    CPC分类号： G01N33/5008 ,  C07K14/57509 ,  G01N33/502 ,  G01N33/566 ,  G01N33/68 ,  G01N33/6842 ,  G01N33/74 ,  A61K38/00 ,  G01N2333/5751 ,  Y10S514/805 ,  Y10S930/26

    摘要： Novel cyclic CRF agonist peptides have the amino acid sequence: (cyclo 30-33)Ac-Pro-Pro-Ile-Ser-Leu-Asp-Leu-Thr-D-Phe-His-Leu-Leu-Arg-Glu-Val-Leu-Glu-Nle-Ala-Arg-Ala-Glu-Gln-Leu-Ala-Gln-R.sub.30 -Ala-R.sub.32 -R.sub.33 -Asn-Arg-Lys-Leu-Nle-Glu-Ile-Ile-NH.sub.2 wherein R.sub.30 is Glu or Cys; R.sub.32 is His or a D-amino acid such as D-His, D-Arg or similar; R.sub.33 is Lys, Orn or Cys. The N-terminus may be extended by Ser-Glu-Glu. Lys may be substituted for Arg.sup.23, and its side chain connected by a lactam bridge to Glu.sup.20 to form a bicyclic peptide. Certain disclosed CRF agonists include: (cyclo 30-33)�Ac-Pro.sup.4, D-Phe.sup.12, Nle.sup.21,38, D-His.sup.32, Glu.sup.30, Lys.sup.33 !r/hCRF(4-41), (cyclo 30-33)�Ac-Pro.sup.4, D-Phe.sup.12, Nle.sup.21,38, D-His.sup.32, Glu.sup.30, Orn.sup.33 !r/hCRF(4-41), (cyclo 30-33)�Ac-Pro.sup.4, D-Phe.sup.12, Nle.sup.21,38, Cys.sup.30,33, D-His.sup.32 !r/hCRF(4-41), (bicyclo 20-23,30-33)�Ac-Pro.sup.4, D-Phe.sup.12, Nle.sup.21,38, Lys.sup.23,33, Glu.sup.30, D-His.sup.32 !-r/hCRF(4-41), (cyclo 30-33)�Ac-Pro.sup.4, D-Phe.sup.12, Nle.sup.21,38, CML.sup.27, Glu.sup.30, imBzlD-His.sup.32, Lys.sup.33 !r/hCRF(4-41) and (cyclo 30-33)�Ac-Pro.sup.4, D-Phe.sup.12, Nle.sup.21,38, Glu.sup.30, D-Arg.sup.32, Lys.sup.33 !r/hCRF(4-41). Labelled agonists such as (cyclo 30-33)�I.sup.125 Tyr.sup.o, D-Phe.sup.12, Nle.sup.21,38, Glu.sup.30, D-His.sup.32, Lys.sup.33 !r/hCRF and (cyclo 30-33)�I.sup.125 D-Tyr.sup.3, D-Phe.sup.12, Nle.sup.21,38, Glu.sup.30, D-His.sup.32, Lys.sup.33 !r/hCRF(3-41) are useful in screening for more potent agonists.

    摘要翻译： 新型循环CRF激动剂肽具有氨基酸序列：（环30-33）Ac-Pro-Pro-Ile-Ser-Leu-Asp-Leu-Thr-D-Phe-His-Leu-Leu-Arg-Glu-Val -Leu-Glu-Nle-Ala-Arg-Ala-Glu-Gln-Leu-Ala-Gln-R30-Ala-R32-R33-Asn-Arg-Lys-Leu-Nle-Glu-Ile-Ile-NH2 是Glu或Cys; R32是His或D-氨基酸，例如D-His，D-Arg或类似物; R33是Lys，Orn或Cys。 N末端可以被Ser-Glu-Glu延伸。 Lys可以代替Arg23，其侧链通过内酰胺桥连接至Glu20以形成双环肽。 某些公开的CRF激动剂包括：（环30-33）[Ac-Pro4，D-Phe12，Nle21,38，D-H​​is32，Glu30，Lys33] r / hCRF（4-41），（环30-33）[Ac -Pro4，D-Phe12，Nle21,38，D-H​​is32，Glu30，Orn33] r / hCRF（4-41），（环30-33）[Ac-Pro4，D-Phe12，Nle21,38，Cys30,33 ，D-His32] r / hCRF（4-41），（双环20-23,30-33）[Ac-Pro4，D-Phe12，Nle21,38，Lys23,33，Glu30，D-His32] -r / hCRF（4-41），（环30-33）[Ac-Pro4，D-Phe12，Nle21,38，CML27，Glu30，imBzlD-His32，Lys33] r / hCRF（4-41）和（环30-33 ）[Ac-Pro4，D-Phe12，Nle21,38，Glu30，D-Arg32，Lys33] r / hCRF（4-41）。 标记的激动剂如（环30-33）[I125Tyro，D-Phe12，Nle21,38，Glu30，D-His32，Lys33] r / hCRF和（环30-33）[I125D-Tyr3，D-Phe12，Nle21， 38，Glu30，D-His32，Lys33] r / hCRF（3-41）可用于筛选更有效的激动剂。

    Urine-based immuncassay for urocirtub 3 abd duagbisus if skeeo aobea
    5.
    发明申请
    Urine-based immuncassay for urocirtub 3 abd duagbisus if skeeo aobea 审中-公开
    用于urocirtub 3的腹膜免疫球蛋白，如果skeeo aobea

    公开(公告)号：US20160161489A1

    公开(公告)日：2016-06-09

    申请号：US14756545

    申请日：2015-09-15

    申请人： Mark W. Linder ,  Kevin Goudy ,  Roland Valdes, JR.

    发明人： Mark W. Linder ,  Kevin Goudy ,  Roland Valdes, JR.

    IPC分类号： G01N33/577 ,  G01N33/68

    CPC分类号： G01N33/558 ,  C07K16/18 ,  G01N2333/5751 ,  G01N2800/2864

    摘要： The present invention provides a method of identifying and isolating a set of monoclonal and polyclonal antibodies for use in immunometric assays for the detection of UCN III peptide, and the development of a two-site immunoassay for UCN III peptide. Monoclonal antibodies (mAb) have been affinity purified and used to develop a two-site immunometric assay comprising a mAb selected from the list comprising 2F7, 4E3, 4D3, 6D1, 1G10, 2E7, 4F3, 4C3, 5E11, 1A9, 4C4, 4B4, 2G7, 2A4, 1B9, 3H11, 5F2, 4G2, and 2E3 used for capture and a polyclonal antibody used for detection. The immunometric assay of the present invention comprise a method to identify and isolate specific antibodies or fragments thereof establishing the presence and/or amount of a UCN III peptide and detecting the specific binding necessary for determining a sample's UCN III peptide level for correlation with a diagnosis wherein the UCN III peptide level is used to determine whether the subject suffers from OSA.

    摘要翻译： 本发明提供鉴定和分离一组单克隆抗体和多克隆抗体的方法，用于免疫测定用于检测UCN III肽，以及开发用于UCN III肽的双位点免疫测定。 单克隆抗体（mAb）已经被亲和纯化并用于开发双位点免疫测定，其包含选自包含2F7,4E3,4D6,6D1,1G10,2E7,4F3,4C3,5E11,1A9,4C4,4B4的mAb ，用于捕获的2G7,2A4,1B9,3H11,5F2,2GP2和2E3以及用于检测的多克隆抗体。 本发明的免疫测定法包括鉴定和分离特异性抗体或其片段的方法，确定UCN III肽的存在和/或量，并检测确定样品的UCN III肽水平与诊断相关性所需的特异性结合 其中UCN III肽水平用于确定受试者是否患有OSA。

    Diagnosis
    6.
    发明申请
    Diagnosis 审中-公开
    诊断

    公开(公告)号：US20060183174A1

    公开(公告)日：2006-08-17

    申请号：US11055668

    申请日：2005-02-11

    申请人： Leong Ng

    发明人： Leong Ng

    IPC分类号： G01N33/537

    CPC分类号： G01N33/573 ,  G01N33/6893 ,  G01N2333/4737 ,  G01N2333/5751 ,  G01N2333/58 ,  G01N2333/908 ,  G01N2800/325

    摘要： A method for screening, diagnosis or prognosis of heart failure in a mammalian subject, for determining the stage or severity of heart failure in a mammalian subject, for identifying a mammalian subject at risk of developing heart failure, or for monitoring the effect of therapy administered to a mammalian subject having heart failure included measuring the level of myeloperoxidase (MPO) in a sample of bodily fluid from the mammalian subject. Methods for monitoring the cardiac health of a mammalian subject are further included. Kits for carrying out such methods are also provided.

    摘要翻译： 用于确定哺乳动物受试者心脏衰竭的阶段或严重程度的哺乳动物受试者的心力衰竭的筛选，诊断或预后的方法，用于鉴定患有心力衰竭风险的哺乳动物受试者，或用于监测施用的治疗效果 涉及具有心力衰竭的哺乳动物受试者包括测量来自哺乳动物受试者的体液样品中髓过氧化物酶（MPO）的水平。 进一步包括监测哺乳动物受试者的心脏健康的方法。 还提供了用于执行这种方法的套件。

    Cyclic CRF analogs
    8.
    发明授权
    Cyclic CRF analogs 失效
    循环CRF类似物

    公开(公告)号：US5663292A

    公开(公告)日：1997-09-02

    申请号：US353928

    申请日：1994-12-12

    申请人： Jean E. F. Rivier

    发明人： Jean E. F. Rivier

    IPC分类号： G01N33/15 ,  A61K38/00 ,  A61K38/04 ,  A61K45/00 ,  A61P25/00 ,  A61P29/00 ,  A61P35/00 ,  C07K14/575 ,  G01N33/50 ,  G01N33/566 ,  G01N33/68 ,  G01N33/74 ,  C07K14/695 ,  C07K7/64

    CPC分类号： G01N33/5008 ,  C07K14/57509 ,  G01N33/502 ,  G01N33/566 ,  G01N33/68 ,  G01N33/6842 ,  G01N33/74 ,  A61K38/00 ,  G01N2333/5751 ,  Y10S514/805 ,  Y10S930/26

    摘要： Improved CRF antagonist peptides have the formula: ##STR1## wherein R.sub.30 is Cys or Glu; R.sub.33 is Cys, Lys or Orn; provided that when R.sub.30 is Cys, R.sub.33 is Cys and when R.sub.30 is Glu, R.sub.33 is Lys or Orn. The N-terminus may be extended by Asp-Leu-Thr. Lys may be substituted for Arg.sup.23 and its side chain connected by a lactam bridge to Glu.sup.20 to form a dicyclic peptide. Specific CRF antagonists disclosed include (cyclo 30-33) [D-Phe.sup.12, Nle.sup.21,38, Glu.sup.30, Lys.sup.33 ]rCRF(12-41); (cyclo 30-33) [D-Phe.sup.12, Nle.sup.21,38, Glu.sup.30, Orn.sup.33 ]rCRF(12-41), (cyclo 30-33) [D-Phe.sup.12, Nle.sup.21,38, Cys.sup.30,33 ]rCRF (12-41) and (bicyclo 20-23,30-33) [D-Phe.sup.12, Nle.sup.21,38, Lys.sup.23,33, Glu.sup.30 ]-rCRF(12-41).

    摘要翻译： 改进的CRF拮抗剂肽具有下式：（环30-33）DPheHisLeuLe​​uArgGluVal LeuGluNleAlaArgAlaGluGlnLeu LeuNleGluIleIleNH2其中R30是Cys或Glu; R33是Cys，Lys或Orn; 条件是当R30为Cys时，R33为Cys，当R30为Glu时，R33为Lys或Orn。 N末端可以被Asp-Leu-Thr延伸。 Lys可被Arg23取代，其侧链通过内酰胺桥连接至Glu20以形成双环肽。 公开的具体CRF拮抗剂包括（环30-33）[D-Phe12，Nle21,38，Glu30，Lys33] rCRF（12-41）; （环30-33）[D-Phe12，Nle21,38，Glu30，Orn33] rCRF（12-41），（环30-33）[D-Phe12，Nle21,38，Cys30,33] rCRF（12-41 ）和（双环20-23,30-33）[D-Phe12，Nle21,38，Lys23,33，Glu30] -rCRF（12-41）。

    METHODS FOR DETERMINING WHETHER A PATIENT IS LIKELY TO BENEFIT FROM TREATMENT WITH A THERAPEUTIC FORMULATION
    9.
    发明申请
    METHODS FOR DETERMINING WHETHER A PATIENT IS LIKELY TO BENEFIT FROM TREATMENT WITH A THERAPEUTIC FORMULATION 审中-公开

    公开(公告)号：US20190250173A1

    公开(公告)日：2019-08-15

    申请号：US16340674

    申请日：2017-10-10

    申请人： Iconic Intellectual Property Limited

    发明人： Deirdre Patricia McIntosh ,  Syed Ebadat Haq

    IPC分类号： G01N33/74 ,  A61K38/22 ,  G01N33/564 ,  A61P25/00

    CPC分类号： G01N33/74 ,  A61K38/2228 ,  A61K38/33 ,  A61P25/00 ,  G01N33/564 ,  G01N33/6893 ,  G01N33/6896 ,  G01N2333/5751 ,  G01N2333/665 ,  G01N2800/52

    摘要： The present invention relates to a method for determining whether a patient is likely to benefit from treatment with a therapeutic formulation, the method comprising the steps of: (a) determining the concentration of corticotropin releasing hormone (CRH) in a sample from a patient prior to administration of the therapeutic formulation; (b) determining the concentration of CRH in a sample from a patient subsequent to administration of the therapeutic formulation; and (c) comparing the concentration of CRH pre-administration with the concentration of CRH subsequent to administration; wherein an increase in patient CRH concentration subsequent to administration indicates that the patient is likely to benefit from treatment with the therapeutic formulation and wherein no increase or a decrease in patient CRH concentration subsequent to administration indicates that the patient is unlikely to benefit from treatment with the therapeutic formulation. The patient may have multiple sclerosis or systemic sclerosis. The therapeutic formulation may be derived from an ungulate such as a goat and may contain CRH, CRH-binding protein, pro-opiomelanocortin (POMC) and alpha-2 macroglobulin. Also provided are methods of treating a patient with a disorder such as multiple sclerosis or systemic sclerosis.